Endocytic Uptake of Solid Lipid Nanoparticles by the Nasal Mucosa

Nanoparticles may provide unique therapeutic opportunities when administered via the nasal cavity, yet the primary uptake and transfer pathways for these particles within the nasal mucosa are not well understood. The endocytic pathways involved in the uptake of fluorescently labeled, (Nile Red) soli...

Full description

Bibliographic Details
Main Authors: Ammar S. Al Khafaji, Maureen D. Donovan
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Pharmaceutics
Subjects:
Online Access:https://www.mdpi.com/1999-4923/13/5/761
id doaj-7efca141642f4e1b949c22ca54a1f3f3
record_format Article
spelling doaj-7efca141642f4e1b949c22ca54a1f3f32021-06-01T00:38:09ZengMDPI AGPharmaceutics1999-49232021-05-011376176110.3390/pharmaceutics13050761Endocytic Uptake of Solid Lipid Nanoparticles by the Nasal MucosaAmmar S. Al Khafaji0Maureen D. Donovan1Department of Pharmaceutical Science and Experimental Therapeutics, College of Pharmacy, University of Iowa, 115 S. Grand Avenue, Pharmacy Building, Iowa City, IA 52242, USADepartment of Pharmaceutical Science and Experimental Therapeutics, College of Pharmacy, University of Iowa, 115 S. Grand Avenue, Pharmacy Building, Iowa City, IA 52242, USANanoparticles may provide unique therapeutic opportunities when administered via the nasal cavity, yet the primary uptake and transfer pathways for these particles within the nasal mucosa are not well understood. The endocytic pathways involved in the uptake of fluorescently labeled, (Nile Red) solid lipid nanoparticles (SLNs) of different sizes (~30, 60, and 150 nm) were studied using excised bovine olfactory and nasal respiratory tissues. Endocytic activity contributing to nanoparticle uptake was investigated using a variety of pharmacological inhibitors, but none of the inhibitors were able to completely eliminate the uptake of the SLNs. The continued uptake of nanoparticles following exposure to individual inhibitors suggests that a number of endocytic pathways work in combination to transfer nanoparticles into the nasal mucosa. Following exposure to the general metabolic inhibitors, 2,4-DNP and sodium azide, additional, non-energy-dependent pathways for nanoparticle uptake were also observed. While the smallest nanoparticles (30 nm) were the most resistant to the effects of pharmacologic inhibitors, the largest (150 nm) were still able to transfer significant amounts of the particles into the tissues. The rapid nanoparticle uptake observed demonstrates that these lipid particles are promising vehicles to accomplish both local and systemic drug delivery following nasal administration.https://www.mdpi.com/1999-4923/13/5/761solid lipid nanoparticlesendocytosisintranasal drug delivery
collection DOAJ
language English
format Article
sources DOAJ
author Ammar S. Al Khafaji
Maureen D. Donovan
spellingShingle Ammar S. Al Khafaji
Maureen D. Donovan
Endocytic Uptake of Solid Lipid Nanoparticles by the Nasal Mucosa
Pharmaceutics
solid lipid nanoparticles
endocytosis
intranasal drug delivery
author_facet Ammar S. Al Khafaji
Maureen D. Donovan
author_sort Ammar S. Al Khafaji
title Endocytic Uptake of Solid Lipid Nanoparticles by the Nasal Mucosa
title_short Endocytic Uptake of Solid Lipid Nanoparticles by the Nasal Mucosa
title_full Endocytic Uptake of Solid Lipid Nanoparticles by the Nasal Mucosa
title_fullStr Endocytic Uptake of Solid Lipid Nanoparticles by the Nasal Mucosa
title_full_unstemmed Endocytic Uptake of Solid Lipid Nanoparticles by the Nasal Mucosa
title_sort endocytic uptake of solid lipid nanoparticles by the nasal mucosa
publisher MDPI AG
series Pharmaceutics
issn 1999-4923
publishDate 2021-05-01
description Nanoparticles may provide unique therapeutic opportunities when administered via the nasal cavity, yet the primary uptake and transfer pathways for these particles within the nasal mucosa are not well understood. The endocytic pathways involved in the uptake of fluorescently labeled, (Nile Red) solid lipid nanoparticles (SLNs) of different sizes (~30, 60, and 150 nm) were studied using excised bovine olfactory and nasal respiratory tissues. Endocytic activity contributing to nanoparticle uptake was investigated using a variety of pharmacological inhibitors, but none of the inhibitors were able to completely eliminate the uptake of the SLNs. The continued uptake of nanoparticles following exposure to individual inhibitors suggests that a number of endocytic pathways work in combination to transfer nanoparticles into the nasal mucosa. Following exposure to the general metabolic inhibitors, 2,4-DNP and sodium azide, additional, non-energy-dependent pathways for nanoparticle uptake were also observed. While the smallest nanoparticles (30 nm) were the most resistant to the effects of pharmacologic inhibitors, the largest (150 nm) were still able to transfer significant amounts of the particles into the tissues. The rapid nanoparticle uptake observed demonstrates that these lipid particles are promising vehicles to accomplish both local and systemic drug delivery following nasal administration.
topic solid lipid nanoparticles
endocytosis
intranasal drug delivery
url https://www.mdpi.com/1999-4923/13/5/761
work_keys_str_mv AT ammarsalkhafaji endocyticuptakeofsolidlipidnanoparticlesbythenasalmucosa
AT maureenddonovan endocyticuptakeofsolidlipidnanoparticlesbythenasalmucosa
_version_ 1721414383118057472